Market Overview

Benzinga's Top #PreMarket Gainers

Related ALNY
Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia
The Biotech Stock With The Biggest Head Of Steam
Related MRK
Merck Presents First Phase 3 Data In Japanese Patients for Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes
Is Merck & Co., Inc. A Leader In A Red Hot Market?
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares jumped 35.93% to $90.00 in pre-market trading after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

Beam (NYSE: BEAM) shares gained 25.93% to $84.35 in the pre-market after the company agreed to be acquired by Suntory Holdings for $83.50 per share in cash.

NII Holdings (NASDAQ: NIHD) surged 20.81% to $2.70 in the pre-market session after the company and Telefonica signed agreements to provide wholesale voice and data services to Nextel in Brazil and Mexico.

Clovis Oncology (NASDAQ: CLVS) soared 6.99% to $79.15 in the pre-market trading after the company announced 2014 objectives and financial outlook.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (ALNY + BEAM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional